| Literature DB >> 23837942 |
Francesca Lobefalo1, Mario Bignardi, Giacomo Reggiori, Angelo Tozzi, Stefano Tomatis, Filippo Alongi, Antonella Fogliata, Anna Gaudino, Piera Navarria, Luca Cozzi, Marta Scorsetti, Pietro Mancosu.
Abstract
BACKGROUND: To assess the dosimetric effect induced by inter-observer variability in target definition for 3D-conformal RT (3DCRT) and volumetric modulated arc therapy by RapidArc (RA) techniques for rectal cancer treatment.Entities:
Mesh:
Year: 2013 PMID: 23837942 PMCID: PMC3720254 DOI: 10.1186/1748-717X-8-176
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Figure 1A schematic representation of the PTV analysis is presented: the four physicians defined four different targets on the same patient, for each patient four plans were optimized on the different PTVs. During the DVH evaluation the PTV on which the target was optimized was called target PTV, while the other targets present on the same CT series were called non-target PTVs. Obviously all targets were both target and non-target PTVs according to the plan considered. This procedure was performed for each patient and for the two planning techniques (3DCRT and RA) before and after the introduction of the guidelines.
Figure 2Four different contours of CTVs superimposed on a axial section of a CT image pre (left) and post (right) the introduction of guidelines.
Analysis of the CTVs volume contouring pre and post the introduction of guidelines
| 1 | 745 | 336 | [656; 992] | 45 | 1.51 |
| 2 | 772 | 682 | [528; 1210] | 81 | 2.08 |
| 3 | 545 | 494 | [380; 874] | 91 | 2.30 |
| 4 | 499 | 467 | [366; 833] | 94 | 2.28 |
| 5 | 540 | 302 | [415; 716] | 56 | 1.73 |
| 6 | 463 | 248 | [330; 578] | 54 | 1.75 |
| 7 | 559 | 117 | [494; 611] | 21 | 1.24 |
| 8 | 722 | 307 | [618; 925] | 43 | 1.50 |
| 9 | 648 | 480 | [486; 966] | 74 | 1.99 |
| 10 | 994 | 423 | [790; 1213] | 43 | 1.54 |
| - | |||||
| - | |||||
| - | |||||
| 1 | 797 | 98 | [848; 750] | 12 | 1.13 |
| 2 | 666 | 254 | [771; 518] | 38 | 1.49 |
| 3 | 496 | 136 | [565; 429] | 27 | 1.32 |
| 4 | 400 | 31 | [417; 386] | 8 | 1.08 |
| 5 | 483 | 40 | [504; 465] | 8 | 1.09 |
| 6 | 406 | 153 | [483; 331] | 38 | 1.46 |
| 7 | 502 | 168 | [574; 406] | 33 | 1.41 |
| 8 | 608 | 79 | [642; 564] | 13 | 1.14 |
| 9 | 574 | 132 | [635; 503] | 23 | 1.26 |
| 10 | 1019 | 283 | [1174; 891] | 28 | 1.32 |
| - | |||||
| - | |||||
| - | |||||
Results from the analysis of the Agreement Index
| Mean; | 0.39 | 0.60 | 0.62 | 0.66 | 0.58 | 0.55 | 0.60 |
| [min; max] | [0.27; 0.51] | [0.48; 0.76] | [0.44; 0.73] | [0.53; 0.78] | [0.44; 0.70] | [0.42; 0.65] | [0.50; 0.74] |
| St. Dev | 0.08 | 0.08 | 0.10 | 0.07 | 0.08 | 0.08 | 0.09 |
| Err% | 20.7 | 13.6 | 15.9 | 10.2 | 14.0 | 14.1 | 14.2 |
| | |||||||
| Mean; | 0.64 | 0.65 | 0.78 | 0.76 | 0.63 | 0.64 | 0.75 |
| [min; max] | [0.46; 0.75] | [0.53; 0.77] | [0.62; 0.86] | [0.58; 0.88] | [0.51; 0.77] | [0.58; 0.70] | [0.56; 0.88] |
| St. Dev | 0.11 | 0.07 | 0.09 | 0.11 | 0.09 | 0.04 | 0.11 |
| Err% | 17.6 | 10.8 | 11.9 | 14.0 | 13.7 | 6.7 | 14.6 |
Figure 3Isodose distributions for an example patient for (up) 3D-CRT (low) RA optimized on PTVs defined by two physicians before the introduction of guidelines. Doses are shown in colorwash ranging from 110% to 85% of the prescription dose. The arrows highlight an area (red rectangle in the figure) that is differently covered by 3D-CRT and RA. An under-dosage of the area is induced by the RA sculpting shape in comparison to the 3D-CRT’s coverage.
Figure 4Isodose distributions for an example patient for (up) 3D-CRT (low) RA optimized on PTVs defined by two physicians after the introduction of guidelines. Doses are shown in colorwash ranging from 110% to 85% of prescription dose. The arrows highlight an area that is differently covered by 3D-CRT and RA. An under-dosage of the area is induced by the RA sculpting shape in comparison to the 3D-CRT’s coverage. To be noticed the underdosage area is lower than before the guidelines introduction.
Summery of DVH analysis for PTV, bladder and femurs
| | | ||||
| V95% [%] | 99.8 ± 0.2 | 99.9 ± 0.1 | 99.7 ± 0.2 | 99.7 ± 0.2 | - |
| | | ||||
| V95% [%] | 93.7 ± 9.2 | 96.6 ± 4.9 | 86.5 ± 13.8 | 94.5 ± 7.5 | a,b,d,f |
| | | ||||
| D2% [Gy] | 48.5 ± 5.1 | 49.0 ± 5.2 | 47.4 ± 3.6 | 46.1 ± 4.2 | - |
| Mean [Gy] | 33.4 ± 8.5 | 30.1 ± 6.5 | 32.1 ± 5.7 | 30.6 ± 3.8 | c |
| D30% [Gy] | 25.9 ± 5.4 | 18.3 ± 5.7 | 18.7 ± 3.3 | 17.6 ± 2.1 | a,b,c |
| V40Gy [%] | 20.7 ± 12.5 | 14.9 ± 9.5 | 11.9 ± 10.1 | 8.1 ± 5.4 | a,b,c,d,e,f |
| | | ||||
| Mean [Gy] | 32.0 ± 7.5 | 29.9 ± 6.6 | 19.7 ± 4.5 | 18.4 ± 1.9 | b,c,d,e |
| D2% [Gy] | 41.7 ± 5.6 | 42.7 ± 4.7 | 28.2 ± 7.4 | 28.1 ± 3.9 | b,c,d,e |
| | | ||||
| Mean [Gy] | 31.9 ± 7.0 | 30.2 ± 6.7 | 18.5 ± 4.4 | 20.1 ± 4.7 | b,c,d,e |
| D2% [Gy] | 41.7 ± 5.4 | 42.5 ± 5.3 | 28.7 ± 7.3 | 28.0 ± 6.8 | b,c,d,e |
The p < 0.05 for: a (3D-Pre vs 3D Post); b (3D-Pre vs RA-Pre); c (3D-Pre vs RA-Post); d (3D Post vs Ra-Pre); e (3D-Post vs RA-Post); f (RA-Pre vs RA-Post).
Figure 5Cumulative histogram representing the number of plans (%) with a certain non-target PTV volume fraction covered by the 95% isodose. For example for 3D pre 83% of the plans had at least 85% of the non-target PTV volume covered by the 95% isodose.